On April 20, 2022 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the UBS Global Healthcare Conference on Tuesday, May 24th. Mathai Mammen, Executive Vice President, Pharmaceuticals R&D, will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time) (Press release, Johnson & Johnson, APR 20, 2022, View Source;johnson-to-participate-in-the-ubs-global-healthcare-conference-301529498.html [SID1234612599]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately 48 hours after the live webcast.